Results 141 to 150 of about 9,833 (206)

A case series of vildagliptin-associated bullous pemphigoid - Rare side effect.

Indian J Pharmacol
Shahi MK, Ashwin JV, Singh A, Gupta S, Surya K.   +4 more
europepmc   +1 more source

Correction: Unravelling the mechanism by which vildagliptin and linagliptin inhibit pyroptosis in lung injury through the NLRP3 inflammatory pathway in type 1 diabetic rats. [PDF]

Sci Rep
Sedik AA, El-Nasr NMEA, Khalil WKB, El-Mosallamy AEMK.   +3 more
europepmc   +1 more source

Efficacy and Safety of Once-Weekly Trelagliptin As Compared to Twice-Daily Vildagliptin in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Phase 3, Non-inferiority Clinical Trial. [PDF]

Cureus
Dewan B, Shinde S, Roy S.
europepmc   +1 more source

Comparison of renal function of the patients receiving linagliptin or vildagliptin in uncontrolled type 2 diabetes mellitus: An observational study in the backdrop of the COVID-19 pandemic.

Indian J Pharmacol
Chaudhuri S, Biswas S, Mukhopadhyay S, Dasgupta S.   +3 more
europepmc   +1 more source

SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis. [PDF]

J Transl Med
Rostami-Afshari B, Elremaly W, Franco A, Elbakry M, Akoume MY, Boufaied I, Moezzi A, Leveau C, Rompré P, Godbout C, Mella O, Fluge Ø, Moreau A.   +12 more
europepmc   +1 more source

Dual therapy with vildagliptin and sacubitril/valsartan alleviates portal hypertension and inhibits soluble epoxide hydrolase in cirrhotic rats. [PDF]

World J Gastroenterol
Oyama M, Kaji K, Nishimura N, Hanatani J, Nakatani T, Nishimura N, Shibamoto A, Asada S, Tsuji Y, Kitagawa K, Sato S, Namisaki T, Yoshiji H.   +12 more
europepmc   +1 more source

Identification, Isolation and Structural Elucidation of New Inner Salt Impurity in Vildagliptin and Metformin Tablet by Using Supercritical Fluid Chromatography, NMR, HRMS. [PDF]

J Sep Sci
Meganathan SK, Sahoo BK, Reddy YR, Rajani K, Reddy PR.   +4 more
europepmc   +1 more source

Surfing the vildagliptin tsunami

Indian Journal of Endocrinology and Metabolism, 2020
openaire   +3 more sources

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin [PDF]

core   +1 more source

Dipeptidyl Peptidase-4 Inhibitors Associated with Lower Psoriatic Disease Risk in Type 2 Diabetes: A 13-Year Nationwide Cohort Study with Mechanistic Validation. [PDF]

Acta Derm Venereol
Hung CT, Chung CH, Weng TH, Tsai CT, Chien WC, Chang YL.   +5 more
europepmc   +1 more source